March 06, 2026 03:22 pm (IST)
Emerging markets affect Dr Reddy's Laboratories' December quarter performance
Hyderabad, Feb 9 (IBNS) Dr Reddy's Laboratories Ltd announced its consolidated financial results on Tuesday for the quarter ended December 31, 2015, where it posted consolidated revenue of ₹39.7 billion, up 3 per cent from the same period in 2014, largely because the healthy performance in North America Generics (NAG), Europe and India were partially offset by emerging markets, which were impacted by unfavorable macro-economic conditions.
Revenues from the Global Generics segment for the reported quarter was ₹33.6 billion, up 7 per cent from the year-ago quarter, primarily driven by North America, Europe and India.
Revenues from the Pharmaceutical Services and Active Ingredients (PSAI) segment was ₹5.1 billion in the reported quarter, and declined by 17 per cent from the same quarter a year ago.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Defence stock on fire! Mazagon Dock Shipbuilders Limited jumps 8% as massive Rs 99,000 crore deal nears approval
Fri, Mar 06 2026
Hormuz flashpoint: Iran targets Western shipping — Could India escape a global oil shock?
Thu, Mar 05 2026
Oil tankers halted, insurance pulled — Is Trump’s Hormuz gamble about to cost India dearly?
Wed, Mar 04 2026
Rs 9.7 lakh crore wiped out! Sensex tanks, rupee breaches 92 amid Middle East crisis
Wed, Mar 04 2026
Big investment alert! Bajaj Life unveils new opportunities fund — Should you jump in?
Mon, Mar 02 2026
Gold, silver surge as Middle East conflict sparks safe-haven buying
Mon, Mar 02 2026
